Blockades of these receptors such as PD-1 and CTLA-4 can reverse the state and reactivate the immune response thereby stopping tumor progression (6, 42–45), suggesting the great potential of immune checkpoint blockade therapies in this regard. Here, CTLA4 is linked to neoplasm.